UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 9, 2015

 

Trovagene, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-35558

 

27-2004382

(State or other jurisdiction

 

(Commission File

 

IRS Employer

of incorporation or organization)

 

Number)

 

Identification No.)

 

11055 Flintkote Avenue, Suite A

San Diego, CA 92121

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (858) 952-7570

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                           Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 1.01                                            Entry into Material Definitive Agreements.

 

On December 9, 2015, the Board of Directors (the “Board”) of Trovagene, Inc. (the “Company”) approved a form of indemnification agreement to be entered into by the Company with each of its directors and executive officers.  In general, each of the indemnification agreements provide, to the fullest extent permitted or provided by the Company’s certificate of incorporation, by-laws, or by Delaware law, indemnification against expenses, damages, losses, liabilities, judgments, fines, penalties and amounts paid in settlement relating to, arising out of or resulting from (i) any actual, alleged or suspected act or failure to act by the indemnitee in his or her capacity as a director or officer of the Company or (ii) indemnitee’s status as a current or former director, officer or employee of the Company. In addition, the indemnification agreement provides that the Company will pay in advance of a final disposition of a claim related expenses as and when incurred by the indemnitee.

 

The description of the indemnification agreements does not purport to be complete and is qualified in its entirety by reference to the form of the indemnification agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

 

Item 5.05                                            Amendments to the Registrant’s Code of Ethics; or Waiver of a Provision of the Code of Ethics.

 

As part of its periodic review of the corporate governance matters of the Company, the Company’s Board adopted and approved certain amendments to the Company’s Code of Business Conduct and Ethics (the “Code”) on December 9, 2015.  The amendments are intended to update the Code to better conform to current best practices and include expanded guidelines, including with respect to the Company’s Insider Trading Policy, Anti-Corruption and Antitrust Laws, the Food, Drug and Cosmetic Act and Interactions with the U.S. Food and Drug and Administration.  The amendments to the Code also provide more detailed guideless with respect to conflicts of interest, corporate opportunities, political contributions and activities as well as competition and fair dealing.

 

The description of the amendments to the Code contained in this report is qualified in its entirety by reference to the full text of the Code filed as Exhibit 14.1 to this Current Report on Form 8-K. The Code, as amended, will be made available in the Corporate Governance section of the Company’s website at www.trovagene.com.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

10.1

Form of Indemnification Agreement

14.1

Code of Conduct and Ethics, as amended on December 9, 2015

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:     December 15, 2015

 

 

 

TROVAGENE, INC.

 

 

 

 

 

By:

/s/ Antonius Schuh

 

 

Antonius Schuh

 

 

Chief Executive Officer

 

2


Exhibit 10.1

 

TROVAGENE, INC.

 

INDEMNIFICATION AGREEMENT

 

This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of                  , 20   by and between Trovagene, Inc., a Delaware corporation (the “Company”), and                           (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.

 

RECITALS

 

WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company from certain liabilities. The By-Laws (the “By-Laws”) of the Company and the Certificate of Incorporation of the Company (“the Certificate of Incorporation”) require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”). The By-Laws and the Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;

 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary for the Company to contractually obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

 

WHEREAS, this Agreement is a supplement to and in furtherance of the By-Laws and the Certificate of Incorporation and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder;

 

WHEREAS,  Indemnitee does not regard the protection available under the By-Laws and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified; and

 

1



 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

 

Section 1.  Services to the Company .   Indemnitee agrees to [continue to] serve as a [director] [officer] [employee] [agent] of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to keep Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company and Indemnitee. Indemnitee specifically acknowledges that Indemnitee’s employment with the Company, if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company, other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the By-Laws, and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as an [officer] [director] [employee] [agent] of the Company.

 

Section 2.  Definitions .   As used in this Agreement:

 

(a)          References to “agent” shall mean any person who is or was a director, officer, or employee of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other Enterprise at the request of, for the convenience of, or to represent the interests of the Company.

 

(b)          A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

 

(i)                          Acquisition of Stock by Third Party.  Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing more than fifty percent (50%) or more of the combined voting power of the Company’s then outstanding securities;

 

(ii)                       Change in Board.  During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;

 

(iii)                    Corporate Transactions.  The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 51% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;

 

(iv)                   Liquidation.  The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and

 

2



 

(v)                      Other Events.  There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.

 

For purposes of this Section 2(b), the following terms shall have the following meanings:

 

(A)        “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

 

(B)        “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

(C)        “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.

 

(c)           “Corporate Status” describes the status of a person who is or was a director, officer, employee or agent of the Company or of any other corporation, limited liability company, partnership or joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company.

 

(d)          “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

 

(e)           “Enterprise” shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary.

 

(f)            “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee’s counsel as being reasonable shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

(g)           “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for

 

3



 

indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

(h)          The term “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him or of any action on his part while acting as director or officer of the Company, or by reason of the fact that he is or was serving at the request of the Company, including prior to the date of this Agreement, as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.

 

(i)              Reference to “other enterprise” shall include employee benefit plans; references to “fines” shall include any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

Section 3.  Indemnity in Third-Party Proceedings .   The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding had no reasonable cause to believe that his conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the By-Laws, vote of the Company’s stockholders or disinterested directors or applicable law.

 

Section 4.  Indemnity in Proceedings by or in the Right of the Company .   The Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith

 

4



 

and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification.

 

Section 5.  Indemnification for Expenses of a Party Who is Wholly or Partly Successful . Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

Section 6.  Indemnification For Expenses of a Witness .   Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise asked to participate in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

 

Section 7.  Partial Indemnification .  If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.

 

Section 8.  Additional Indemnification .

 

(a)          Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee in connection with the Proceeding.

 

(b)          For purposes of Section 8(a), the meaning of the phrase “to the fullest extent permitted by applicable law” shall include, but not be limited to:

 

(i)                          to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and

 

(ii)                       to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.

 

Section 9.  Exclusions .   Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:

 

5



 

(a)          for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or

 

(b)          for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act); or

 

(c)           except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.

 

Section 10.  Advances of Expenses .   In accordance with Section 3 of Article XI of the By-Laws, and notwithstanding any provision of this Agreement to the contrary, the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. This Section 10 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 9.

 

Section 11.  Procedure for Notification and Defense of Claim .

 

(a)          Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such action, suit or proceeding. The omission by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement.

 

6



 

The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.

 

(b)          The Company will be entitled to participate in the Proceeding at its own expense.

 

Section 12.  Procedure Upon Application for Indemnification .

 

(a)          Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even if less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even if less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the Company; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

 

(b)          In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in this Section 12(b). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided , however , that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section 11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel

 

7



 

shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

 

Section 13.  Presumptions and Effect of Certain Proceedings .

 

(a)          In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

(b)          Subject to Section 14(e), if the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 13(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 12(a) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) of this Agreement.

 

(c)           The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

 

(d)          Reliance as Safe Harbor . For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Enterprise. The

 

8



 

provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.

 

(e)           Actions of Others . The knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

Section 14.  Remedies of Indemnitee .

 

(a)          Subject to Section 14(e), in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5, 6 or 7 or the last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 8 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 14(a); provided , however , that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

 

(b)          In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 14 the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.

 

(c)           If a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

(d)          The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of

 

9



 

Indemnitee’s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company if Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification and advancement shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater.

 

(e)           Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.

 

Section 15.  Non-exclusivity; Survival of Rights; Insurance; Subrogation .

 

(a)          The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the By-Laws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the By-Laws, the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

(b)          The Company shall use its best efforts to maintain an insurance policy or policies providing liability insurance for directors and officers in effect at all times.  To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

 

(c)           In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

10



 

(d)          The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

(e)           The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise.

 

Section 16.  Duration of Agreement .   This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a [director] [officer] [employee] [agent] of the Company or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his heirs, executors and administrators.

 

Section 17.  Severability .   If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

 

Section 18.  Enforcement .

 

(a)          The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.

 

(b)          This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the By-Laws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

 

Section 19.  Modification and Waiver .   No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 

11



 

Section 20.  Notice by Indemnitee .   Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise.

 

Section 21.  Notices .   All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:

 

(i)                          If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company.

 

(ii)                       If to the Company to

 

Trovagene, Inc.

11055 Flintkote Avenue, Suite A

San Diego, CA 92121

Attention: President and Chief Executive Officer

 

or to any other address as may have been furnished to Indemnitee by the Company.

 

Section 22.  Contribution .   To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (a) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (b) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

Section 23.  Applicable Law and Consent to Jurisdiction .   This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (b) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (c) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably The Corporation Service Company, 2711 Centerville Road, City of Wilmington, County of New Castle, Delaware 19808 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (d) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (e) waive, and agree not to plead or

 

12



 

to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

 

Section 24.  Identical Counterparts .   This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 

Section 25.  Miscellaneous .   Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.

 

 

TROVAGENE, INC.

 

 

 

 

 

By:

 

 

 

 

Title:

 

 

 

 

 

 

INDEMNITEE

 

 

 

 

 

Address:

 

 

 

13


Exhibit 14.1

 

Effective Date:  January 1, 2016

 

TROVAGENE, INC.

 

CODE OF BUSINESS CONDUCT AND ETHICS

 

1.               Introduction

 

We are committed to maintaining the highest standards of ethical, honest and legal business conduct.  This Code of Business Conduct and Ethics (“Code”) reflects the business practices and principles of behavior that support this commitment.  We expect all employees, including officers, and directors of Trovagene, Inc. and its subsidiaries (which are referred to in the Code, collectively, as “Trovagene”) to read and understand the Code and its application to the performance of his or her business responsibilities.  References in the Code to employees are intended to include officers and, as applicable, directors.

 

Officers, managers and other supervisors are expected to develop in employees a sense of commitment to the spirit, as well as the letter, of the Code.  Supervisors are also expected to ensure that all agents and contractors conform to Code standards when working for or on behalf of Trovagene. The compliance environment within each supervisor’s assigned area of responsibility will be a significant factor in evaluating the quality of that individual’s performance. In addition, any employee who makes an exemplary effort to implement and uphold our legal and ethical standards may be recognized for that effort in his or her performance review.  Nothing in the Code alters the at-will employment policy of Trovagene.

 

The Code addresses conduct that is particularly important to ensure proper dealings with the people and entities with which we interact, but reflects only a part of our commitment.  From time to time, we may adopt additional policies and procedures with which our employees, officers and directors are expected to comply, if applicable to them.  However, it is the responsibility of each employee to apply common sense, together with his or her own highest personal ethical standards, in making business decisions where there is no stated guideline in the Code.

 

Action by members of your family, significant others or other persons who live in your household (referred to in the Code as “family members”) also may potentially result in ethical issues to the extent that they involve Trovagene’s business.  For example, acceptance of inappropriate gifts by a family member from one of our suppliers could create a conflict of interest and result in a Code violation attributable to you.  Consequently, in complying with the Code, you should consider not only your own conduct, but also that of your family members, significant others and other persons who live in your household.

 

You should not hesitate to ask questions about whether any conduct could violate the Code, voice concerns or clarify gray areas.  Section 26, “Compliance Standards and Procedures”, below details the compliance resources available to you.  In addition, you should be alert to possible violations of the Code by others and you have the duty to report any known or suspected violations of the Code, without fear of any form of retaliation, as further described in Section 26, “Compliance Standards and Procedures” .

 

Violations of the Code will not be tolerated.  Any employee who violates the standards in the Code may be subject to disciplinary action, which, depending on the nature of the violation and the

 

1



 

history of the employee, may range from a warning or reprimand to and including termination of employment and, in appropriate cases, civil legal action or referral for criminal prosecution.

 

2.               Honest and Ethical Conduct

 

Our policy is to promote high standards of integrity by conducting our affairs in an honest and ethical manner.  The integrity and reputation of Trovagene depends on the honesty, fairness and integrity brought to the job by each person associated with us.  Unyielding personal integrity is the foundation of corporate integrity.

 

3.               Legal Compliance

 

Obeying the law, both in letter and in spirit, is the foundation of this Code.  Our success depends upon each employee operating within legal guidelines and cooperating with local, national and international authorities.  Each Trovagene employee has an obligation, and is expected, to comply with the law, including, but not limited to, in connection with activities associated with their official responsibilities as a Trovagene employee.  We expect employees to understand the legal and regulatory requirements applicable to their business units and areas of responsibility.  We will not tolerate any activity that violates any laws, rules, or regulations, including, without limitation, those applicable to Trovagene.  This includes, without limitation, laws covering the conduct of our clinical and preclinical studies, commercial bribery and kickbacks, marketing, copyrights, trademarks and trade secrets, protection of third party/former employer confidential information, information privacy, insider trading, illegal political contributions, antitrust prohibitions, foreign corrupt practices, offering or receiving gratuities, environmental hazards, employment discrimination or harassment, occupational health and safety, false or misleading financial information or misuse of corporate assets. The fact that, in some countries, certain laws are not enforced or that violation of those laws is not subject to public criticism will not be accepted as an excuse for noncompliance.  If any doubt exists about whether a course of action is lawful, you should seek advice immediately from either the Healthcare Compliance Officer or the Corporate Compliance Officer.

 

Disregard of the law, whether in connection with your official responsibilities as a Trovagene employee or otherwise, will not be tolerated.  Violation of domestic or foreign laws, rules and regulations may subject an individual, as well as Trovagene, to civil and/or criminal penalties.  Violation of domestic or foreign laws, rules and regulations may also subject an individual to disciplinary action by Trovagene as further described in Section 26, “Compliance Standards and Procedures”.   You should be aware that your conduct and records, including emails, are subject to internal and external audits, and to discovery by third parties in the event of a government investigation or civil litigation.  It is in everyone’s best interests to know and comply with our legal and ethical obligations.  Nothing in any other section of this Code shall be interpreted, or deemed, to narrow or limit your obligations under this section or Trovagene’s actions in response to a failure to satisfy such obligations.

 

4.               Insider Trading

 

All employees must comply with Trovagene’s Insider Trading Policy, which explicitly states that employees who have access to confidential (or “inside”) information are not permitted to use or share that information for stock trading purposes or for any other purpose except to conduct our business.  All nonpublic information about Trovagene or about companies with which we do business is considered confidential information.  To use material non-public information in connection with buying or selling

 

2



 

securities, including “tipping” others who might make an investment decision on the basis of this information, is unethical and illegal.  Employees must exercise the utmost care when handling material inside information.

 

5.               International Business & Trade Laws

 

Our employees are expected to comply with the applicable laws in all countries to which they travel, in which they operate and where we otherwise do business, including laws prohibiting bribery, corruption or the conduct of business with specified individuals, companies or countries.  The fact that in some countries certain laws are not enforced or that violation of those laws is not subject to public criticism will not be accepted as an excuse for noncompliance.  In addition, we expect employees to comply with U.S. laws, rules and regulations governing the conduct of business by its citizens and corporations outside the U.S.

 

The U.S. and other countries where Trovagene does business have laws that restrict or prohibit doing business with certain countries and parties.  Likewise, many countries also restrict or prohibit transactions involving certain products and technologies.  These U.S. laws, rules and regulations, which extend to all our activities outside the U.S., include:

 

·                   U.S. Embargoes, which generally prohibit U.S. companies, their subsidiaries and their employees from doing business or traveling to  countries, subject to sanctions imposed by the U.S. government (currently, Cuba, Iran, North Korea, Sudan and Syria), as well as specific companies and individuals identified on lists published by the U.S. Treasury Department;

 

·                   Export Controls, which restrict travel to designated countries or prohibit or restrict the export of goods, services and technology to designated countries, denied persons or denied entities from the U.S., or the re-export of U.S. origin goods from the country of original destination to such designated countries, denied companies or denied entities; and

 

·                   Anti-Boycott Compliance, which prohibits U.S. companies from taking any action that has the effect of furthering or supporting a restrictive trade practice or boycott that is fostered or imposed by a foreign country against a country friendly to the U.S. or against any U.S. person.

 

If you have a question as to whether an activity is restricted or prohibited, you should make every effort to seek assistance from the Corporate Compliance Officer or Healthcare Compliance Officer before taking any action, including giving any verbal assurances that might be regulated by international laws.

 

6.               Anti-Corruption Laws

 

The Foreign Corrupt Practices Act (the “FCPA”) prohibits Trovagene and its employees and agents from offering or giving money or any other item of value to win or retain business or to influence any act or decision of any governmental official, political party, candidate for political office or official of a public international organization.  Doctors employed by government-funded hospitals who serve on formulary committees and employees of health authorities can be considered government officials for purposes of the FCPA.  Stated more concisely, the FCPA prohibits the payment of bribes, kickback or other inducements to foreign officials.  This prohibition also extends to payments to a sales representative or agent if there is reason to believe that the payment will be used indirectly for a prohibited payment to foreign officials.  In addition, the FCPA’s books and records provisions make it illegal to improperly

 

3



 

record transactions subject to the FCPA.  Violation of the FCPA is a crime that can result in severe fines and criminal penalties, as well as disciplinary action by Trovagene as further described in Section 26, “Compliance Standards and Procedures”.

 

Certain small facilitation or “grease” payments to foreign officials may be permissible under the FCPA if customary in the country or locality and intended to secure routine governmental action.  Governmental action is “routine” if it is ordinarily and commonly performed by a foreign official and does not involve the exercise of discretion.  For instance, “routine” functions would include setting up a telephone line.  To ensure legal compliance, all facilitation payments must receive prior written approval from Trovagene’s Corporate Compliance Officer or Healthcare Compliance Officer and must be clearly and accurately reported as a business expense.

 

We must also comply with all local anti-bribery and corruption laws.  In the event local laws and the FCPA differ, the stricter set of laws should be followed.  For example, the U.K. Bribery Act prohibits small facilitation or “grease” payments that may be permissible under the FCPA.  Please notify Trovagene’s Corporate Compliance Officer or Healthcare Compliance Officer if you have any questions concerning these laws.

 

7.               Antitrust

 

Antitrust laws of the U.S. and other countries are designed to protect consumers and competitors against unfair business practices and to promote and preserve competition.  Our policy is to compete vigorously and ethically while complying with all antitrust, monopoly, competition or cartel laws in all countries, states or localities in which Trovagene conducts business.  If you are responsible for areas of the business where these laws apply, you must be aware of them and their implications, including how they apply in the country where you operate.  Antitrust laws impose severe penalties for certain types of violations, including criminal penalties and potential fines and damages of millions of dollars, which may be tripled under certain circumstances.   You should consult Trovagene’s Corporate Compliance Officer or Healthcare Compliance Officer with any questions you may have concerning compliance with these laws.  The following is a summary of actions that are violations of applicable antitrust laws:

 

·                   Price Fixing.  Trovagene may not agree, formally or informally, with its competitors to raise, lower or stabilize prices or any element of price, including discounts and credit terms, or establish or fix the price at which a customer may resell a product.

 

·                   Limitation of Supply.  Trovagene may not agree, formally or informally, with its competitors to limit its production or restrict the supply of its services.

 

·                   Allocation of Business.  Trovagene may not agree, formally or informally, with its competitors to divide or allocate markets, territories or customers.

 

·                   Monopolies.  Trovagene may not engage in any behavior that can be construed as an attempt to monopolize through anti-competitive conduct.

 

·                   Boycott.  Trovagene may not agree, formally or informally, with its competitors to refuse to sell or purchase products from third parties.  In addition, Trovagene may not prevent a customer from purchasing or using non-Trovagene products or services.

 

4



 

·                   Tying.  Trovagene may not require a customer to purchase a product that it does not want as a condition to the sale of a different product that the customer does wish to purchase.

 

8.               Meetings with Competitors

 

Employees should exercise caution in meetings with competitors when discussing marketed products and services.  For purposes of this section, co-promotion and research collaboration partners are not considered competitors.  Any meeting with a competitor may give rise to the appearance of impropriety.  As a result, if you are required to meet with a competitor and have questions concerning proper topics for discussion, you should consult the Corporate Compliance Officer with any questions.  You should try to meet with competitors in a closely monitored, controlled environment for a limited period of time.  The contents of your meeting should be fully documented.  Specifically, you should avoid any communications with a competitor, regardless of how innocent or casual the exchange may be and regardless of the setting, whether business or social, regarding:

 

·                   Prices;

 

·                   Costs;

 

·                   Market share;

 

·                   Allocation of sales territories;

 

·                   Profits and profit margins;

 

·                   Supplier’s terms and conditions;

 

·                   Product or service offerings;

 

·                   Terms and conditions of sale;

 

·                   Production facilities or capabilities;

 

·                   Bids for a particular contract or program;

 

·                   Selection, retention or quality of customers;

 

·                   Distribution; or

 

·                   Methods or channels.

 

9.               Professional Organizations and Trade Associations

 

Employees should be cautious when attending meetings of professional organizations and trade associations at which customers (e.g. healthcare professionals), potential referral sources, or competitors are present.  Attending meetings of professional organizations and trade associations is both legal and proper, if such meetings have a legitimate business purpose.  At such meetings, you should not

 

·                   Discuss pricing policy or other competitive terms, plans for new or expanded facilities or any other proprietary, competitively sensitive information; or

 

5



 

·                   Engage in pre-approval promotion and off-label marketing.

 

Even joking about inappropriate topics, such as pricing strategies, could be misinterpreted or misreported.  If the conversation includes any of the above topics, you should promptly leave the conversation and report the incident to your supervisor, Trovagene’s Healthcare Compliance Officer or Corporate Compliance Officer.  Unless authorized as part of your job responsibilities, you are required to notify your supervisor prior to attending any meeting of a professional organization or trade association where participation relates to Trovagene products or services.

 

10.        Environment; Health and Safety

 

Trovagene is committed to providing a safe and healthy working environment for its employees and to avoiding adverse impact and injury to the environment and the communities in which it does business.  Trovagene employees must comply with all applicable environmental, health and safety laws, regulations and Trovagene standards.  It is your responsibility to understand and comply with the laws, regulations and policies that are relevant to your job.  Failure to comply with environmental, health and safety laws and regulations can result in civil and criminal liability against you and Trovagene, as well as disciplinary action by Trovagene as further described in Section 26, “Compliance Standards and Procedures”.

 

10.1.                      Environment

 

All Trovagene employees should strive to conserve resources and reduce waste and emissions through recycling and other energy conservation measures.  Federal law imposes criminal liability on any person or company that contaminates the environment with any hazardous substance that could cause injury to the community or environment.  Violation of environmental laws can involve monetary fines and imprisonment.  We expect employees to comply with all applicable environmental laws.  You have a responsibility to promptly report any known or suspected violations of environmental laws or any events that may result in a discharge or emission of hazardous materials.

 

10.2.                      Health and Safety

 

Trovagene is committed not only to comply with all relevant health and safety laws, but also to conduct business in a manner that protects the safety of its employees.  All employees are required to comply with all applicable health and safety laws, regulations and policies relevant to their positions.  If you have a concern about unsafe conditions or tasks that present a risk of injury to you, please report these concerns immediately to your supervisor, the Human Resources Department, the Corporate Compliance Officer or the Healthcare Compliance Officer.

 

11.        Employment Practices

 

Trovagene pursues fair employment practices in every aspect of its business.  The following is intended to be a summary of our employment policies and procedures.  Copies of Trovagene’s detailed policies, including its Employee Handbook, are available from the Human Resources Department.  Trovagene employees must comply with all applicable labor and employment laws, including anti-discrimination laws and laws related to freedom of association and privacy.  It is your responsibility to understand and comply with the laws, regulations and policies that are relevant to your job.  Failure to comply with labor and employment laws can result in civil and criminal liability against you and

 

6



 

Trovagene, as well as disciplinary action by Trovagene as further described in Section 26, “Compliance Standards and Procedures”.

 

12.        The Food, Drug and Cosmetic Act (the “FDCA”) and Interactions with the U.S. Food and Drug Administration (the “FDA”)

 

12.1.                      General

 

Trovagene’s product candidates and its operations are subject to extensive and rigorous regulation by the FDA.  The FDA regulates many areas of Trovagene’s operations, including the research, preclinical and clinical testing, and development of medical devices; the submission of data and other information to support FDA approval; the manufacturing, testing and labeling of medical devices; the promotion, distribution, and sale of our medical devices (including the provision of samples to physicians); and the reporting of adverse events and other information to the FDA.  The FDA also regulates the export of medical devices manufactured in the U.S. to international markets and the import to the U.S. of medical devices manufactured outside of the U.S.  Violation of these laws and regulations can result in: severe civil and criminal penalties; adverse publicity for Trovagene; total or partial suspension of production of a Trovagene product; withdrawal of a Trovagene product from the market; exclusion of Trovagene or individuals employed by Trovagene from participation in federal health care programs; and disciplinary action by Trovagene against the responsible individuals, as further described in Section 26, “Compliance Standards and Procedures”.

 

12.2.                      Compliance with the FDCA and FDA Laws and Regulations

 

Trovagene employees with responsibilities in the areas governed by the FDCA and the FDA are required to understand and comply with these laws and regulations.  These employees are expected to have a thorough understanding of the laws, regulations and other relevant standards applicable to their job positions, and to comply with those requirements.  In particular, any promotional discussion and promotional information used or distributed must be complete accurate and not misleading.  Product claims must be consistent with approved labeling and prescribing information. In addition, when discussing approved products, fair and balanced information must be provided — describing all safety information fully and accurately and never misrepresenting or minimizing it in any way.  Trovagene has developed standard operating procedures and provides regular training to aid employees in understanding and complying with the requirements of the FDCA and the FDA.  If any doubt exists regarding whether your job position or a particular course of action is governed by these laws and regulations, you should seek advice immediately from your supervisor and Trovagene’s Healthcare Compliance Officer.

 

13.        Harassment and Discrimination

 

13.1.                      General

 

Trovagene is committed to providing equal opportunity and fair treatment to all individuals on the basis of merit, without discrimination because of race, color, religion, national origin, sex (including pregnancy), sexual orientation, age, disability, veteran status or other characteristic protected by law.  Trovagene also prohibits harassment based on these characteristics in any form, whether physical or verbal and whether committed by supervisors, non-supervisory personnel or non-employees.  Harassment may include, but is not limited to, offensive sexual

 

7



 

flirtations, unwanted sexual advances or propositions, verbal abuse, sexually or racially degrading words, or the display in the workplace of sexually suggestive or racially degrading objects or pictures.

 

13.2.                      Employee Reporting Requirements

 

If you have any complaints about discrimination or harassment, or witness or observe any harassment occurring in the workplace, report such conduct to your supervisor, the Human Resources Department, the Corporate Compliance Officer or the Healthcare Compliance Officer.  All complaints will be treated with sensitivity and discretion.  Your supervisor, the Human Resources Department, the Corporate Compliance Officer, the Healthcare Compliance Officer and Trovagene will protect your confidentiality to the extent possible, consistent with law and Trovagene’s need to investigate your concern.  Trovagene strictly prohibits retaliation against an employee who, in good faith, files a complaint.  Where our investigation uncovers harassment or discrimination, we will take prompt corrective action, which may include disciplinary action by Trovagene as further described in Section 26, “Compliance Standards and Procedures” .

 

13.3.                      Management Reporting Requirements

 

Any member of management who has reason to believe that an employee has been the victim of harassment or discrimination or who receives a report of alleged harassment or discrimination is required to report it to the Corporate Compliance Officer or the Healthcare Compliance Officer immediately.

 

14.        Alcohol and Drugs

 

Trovagene is committed to maintaining a drug-free work place.  All Trovagene employees must comply strictly with Trovagene policies regarding the abuse of alcohol and the possession, sale and use of illegal substances.  Drinking alcoholic beverages is prohibited while on duty or on the premises of Trovagene, except at specified Trovagene-sanctioned events.  Possessing, using, selling or offering illegal drugs and other controlled substances without a valid prescription is prohibited under all circumstances while on duty or on the premises of Trovagene.  Likewise, you are prohibited from reporting for work, or driving a Trovagene vehicle or any vehicle on Trovagene business, while under the influence of alcohol or any illegal drug or controlled substance.

 

15.        Violence Prevention and Weapons

 

The safety and security of Trovagene employees is vitally important.  Trovagene will not tolerate violence or threats of violence in, or related to, the workplace.  If you experience, witness or otherwise become aware of a violent or potentially violent situation that occurs on Trovagene’s property or affects Trovagene’s business you must immediately report the situation to your supervisor, the Human Resources Department, Trovagene’s Corporate Compliance Officer, or Trovagene’s Healthcare Compliance Officer.

 

Trovagene does not permit any individual to have weapons of any kind on Trovagene property or in vehicles, while on the job or off-site while on Trovagene business.  This is true even if you have obtained legal permits to carry weapons.  The only exception to this policy applies to security personnel who are specifically authorized by Trovagene management to carry weapons.

 

8



 

16.        Conflicts of Interest

 

We respect the rights of our employees to manage their personal affairs and investments and do not wish to impinge on their personal lives.  At the same time, employees should avoid conflicts of interest that occur when their personal interests may interfere in any way with the performance of their duties or the best interests of Trovagene.  A conflicting personal interest could result from an expectation of personal gain now or in the future or from a need to satisfy a prior or concurrent personal obligation.  We expect our employees to be free from influences that conflict with the best interests of Trovagene.  Even the appearance of a conflict of interest where none actually exists can be damaging and should be avoided.

 

If you have any questions about a potential conflict or if you become aware of an actual or potential conflict, and you are not an officer or director of Trovagene, you should discuss the matter with your supervisor and with Trovagene’s Corporate Compliance Officer (as further described in Section 17, “Corporate Opportunities” ).  Supervisors may not resolve conflict of interest matters without first seeking the approval of the Corporate Compliance Officer and filing with the Corporate Compliance Officer a written description of the activity.  If the supervisor is involved in the potential or actual conflict, you should discuss the matter directly with the Corporate Compliance Officer.  Officers and directors may seek authorization from the Board of Directors.

 

Factors that may be considered in evaluating a potential conflict of interest are, among others:

 

·                   Whether it may interfere with the employee’s job performance, responsibilities or morale;

 

·                   Whether the employee has access to confidential information;

 

·                   Whether it may interfere with the job performance, responsibilities or morale of others within the organization;

 

·                   Any potential adverse or beneficial impact on our business;

 

·                   Any potential adverse or beneficial impact on our relationships with our customers or suppliers or other service providers;

 

·                   Whether it would enhance or support a competitor’s position;

 

·                   The extent to which it would result in financial or other benefit (direct or indirect) to the employee;

 

·                   The extent to which it would result in financial or other benefit (direct or indirect) to one of our customers, suppliers or other service providers; and

 

·                   The extent to which it would appear improper to an outside observer.

 

Although no list can include every possible situation in which a conflict of interest could arise, the following are examples of situations that may, depending on the facts and circumstances, involve conflicts of interests:

 

9



 

·                   Employment by (including consulting for) or service on the board of a competitor, customer or supplier or other service provider.  Activity that enhances or supports the position of a competitor to the detriment of Trovagene is prohibited, including employment by or service on the board of a competitor.  Employment by or service on the board of a customer or supplier or other service provider is generally discouraged and you must seek authorization from the Corporate Compliance Officer in advance if you plan to take such action.

 

·                   Owning, directly or indirectly, a significant financial interest in any entity that does business, seeks to do business or competes with us.  In addition to the factors described above, persons evaluating ownership for conflicts of interest will consider the size and nature of the investment; the nature of the relationship between the other entity and Trovagene; the employee’s access to confidential information and the employee’s ability to influence Trovagene’s decisions.  If you would like to acquire a financial interest of that kind, you must seek approval in advance.

 

·                   Soliciting or accepting gifts, favors, loans or preferential treatment from any person or entity that does business or seeks to do business with us.  See Section 21, “Competition and Fair Dealing” , for further discussion of the issues involved in this type of conflict.

 

·                   Soliciting contributions to any charity or for any political candidate from any person or entity that does business or seeks to do business with us.

 

·                   Taking personal advantage of corporate opportunities.  See Section 17, “Corporate Opportunities” , for further discussion of the issues involved in this type of conflict.

 

·                   Moonlighting without permission.

 

·                   Conducting our business transactions with your family member or a business in which you have a significant financial interest.  Material related-party transactions approved by the Board of Directors and involving any executive officer or director will be publicly disclosed as required by applicable laws and regulations.

 

·                   Exercising supervisory or other authority on behalf of Trovagene over a co-worker who is also a family member.  The employee’s supervisor and/or the Corporate Compliance Officer will consult with the Human Resources Department to assess the advisability of reassignment.

 

Loans to, or guarantees of obligations of, employees or their family members by Trovagene could constitute an improper personal benefit to the recipients of these loans or guarantees, depending on the facts and circumstances.  Some loans are expressly prohibited by law, and applicable law requires that our Board of Directors approve all loans and guarantees to employees.  As a result, all loans and guarantees by Trovagene must be approved in advance by the Board of Directors.

 

Trovagene’s officers may not, while they are employed by Trovagene, accept offers to serve on boards of, or be concurrently employed by, any other for-profit organization (whether or not a competitor to Trovagene) without prior authorization from our Board of Directors.

 

10



 

17.        Corporate Opportunities

 

You may not take personal advantage of opportunities for Trovagene that are presented to you or discovered by you as a result of your position with us or through your use of corporate property or information. Even opportunities that are acquired privately by you may be questionable if they are related to our existing or proposed lines of business.  Significant participation in an investment or outside business opportunity that is directly related to our lines of business must be pre-approved by Trovagene’s Corporate Compliance Officer.  You cannot use your position with us or corporate property or information for improper personal gain, nor can you compete with Trovagene in any way.

 

18.        Interactions with the Government

 

Trovagene may conduct business with the U.S., state and local governments and the governments of many other countries.  Trovagene is committed to conducting its business with all governments and their representatives with the highest standards of business ethics and in compliance with all applicable laws and regulations, including the special requirements that apply to communications with governmental bodies that have regulatory authority over our products and operations, such as the FDA, government contracts and government transactions.  In your interactions with the government, you should:

 

·                   Be forthright and candid at all times.  No employee should intentionally misstate or omit any material information from any written or oral communication with the government.

 

·                   Ensure that all required written submissions are made to the government and are timely, and that all written submissions, whether voluntary or required, satisfy applicable laws and regulations.

 

·                   Not offer or exchange any gifts, gratuities or favors with, or pay for meals, entertainment, travel or other similar expenses for, government employees.

 

If your job responsibilities include interacting with the government, you are expected to understand and comply with the special laws, rules and regulations that apply to your job position as well as with any applicable standard operating procedures that Trovagene has implemented.  If any doubt exists about whether a course of action is lawful, you should seek advice immediately from your supervisor, Trovagene’s Corporate Compliance Officer and Trovagene’s Healthcare Compliance Officer.

 

Trovagene cooperates with all government agencies in any request for information or facility visits in connection with government investigations.  The Healthcare Compliance Officer represents Trovagene in these investigations and will determine what information is appropriate to supply to investigators.  If you are contacted by any government agency outside of the ordinary course of our business dealings with the government, you should immediately notify your supervisor, Trovagene’s Corporate Compliance Officer and Trovagene’s Healthcare Compliance Officer.

 

19.        Political Contributions and Activities

 

19.1.                      General

 

Trovagene encourages its employees to participate in the political process as individuals.  Employees should be careful to make it clear that their political views and actions are their own, and not made on behalf of Trovagene.  Trovagene funds or assets shall not be used to make a

 

11



 

political contribution to any political party or candidate, unless prior approval has been given by Trovagene’s Corporate Compliance Officer.

 

19.2.                      Guidelines

 

The following guidelines are intended to ensure that any political activity you pursue complies with this policy and to ensure that any political activity you pursue is done voluntarily and with your own resources and time:

 

·                   Contribution of Funds .  You may contribute your personal funds to political parties or candidates.  Trovagene will not reimburse you for personal political contributions.

 

·                   Volunteer Activities .  You may participate in volunteer political activities during non-work time.  You may not participate in political activities during working hours.

 

·                   Use of Trovagene Facilities .  Trovagene’s facilities generally may not be used for political activities (including fundraisers or other activities related to running for office).  However, Trovagene may make its facilities available for limited political functions, including speeches by government officials and political candidates, with the approval of Trovagene’s Corporate Compliance Officer.

 

·                   Use of Trovagene Name .  When you participate in political affairs, you should be careful to make it clear that your views and actions are your own, and not made on behalf of Trovagene.  For instance, neither Trovagene letterhead nor your Trovagene email account should be used to send out personal letters in connection with political activities.

 

20.                                Maintenance of Corporate Books, Records, Documents and Accounts; Financial Integrity; Public Reporting

 

Accurate and reliable records are crucial to our business and form the basis of our financial results, financial reports and other disclosures to the public.  Our records are the source of essential data and information that guide business decision-making and strategic planning and are important in meeting our obligations to customers, suppliers, creditors, employees and others with whom we do business.  The integrity of our records and public disclosure depends on the validity, accuracy and completeness of the information supporting the entries to our books of account.  Therefore, all Trovagene records must be complete, accurate and reliable in all material respects.  The making of false or misleading entries, whether they relate to financial results or test results, is strictly prohibited.  Trovagene records include financial records, personnel records, records relating to our product development, clinical development, manufacturing and regulatory submissions, time sheets, expense reports, invoices and all other records maintained in the ordinary course of our business.  Accordingly, we require that:

 

·                   No entry be made in our books and records that intentionally hides or disguises the nature of any transaction or of any of our liabilities, or misclassifies any transactions as to accounts or accounting periods;

 

·                   Transactions be supported by appropriate documentation;

 

12



 

·                   The terms of sales and other commercial transactions be reflected accurately in the documentation for those transactions and all such documentation be reflected accurately in our books and records;

 

·                   Employees comply with our system of internal controls; and

 

·                   No cash or other assets be maintained for any purpose in any unrecorded or “off-the-books” fund.

 

Our accounting records are also relied upon to produce reports for our management, stockholders and creditors, as well as for governmental agencies.  In particular, we rely upon our accounting and other business and corporate records in preparing the periodic and current reports that we file with the Securities and Exchange Commission (the “SEC”).  Securities laws require that these reports provide full, fair, accurate, timely and understandable disclosure and fairly present our financial condition and results of operations.  Employees who collect, provide or analyze information for or otherwise contribute in any way in preparing or verifying these reports must (i) be familiar with and comply with our disclosure controls and procedures and internal control over financial reporting, and (ii) take all necessary steps to ensure that our financial disclosure is accurate and transparent and that our reports contain all of the information about Trovagene that would be important to enable stockholders and potential investors to assess the soundness and risks of our business and finances and the quality and integrity of our accounting and disclosures.  In addition:

 

·                   No employee may take or authorize any action that would cause our financial records or financial disclosure to fail to comply with generally accepted accounting principles, the rules and regulations of the SEC or other applicable laws, rules and regulations;

 

·                   All employees must cooperate fully with our Finance Department, as well as our independent public accountants and counsel, respond to their questions with candor and provide them with complete and accurate information to help ensure that our books and records, as well as our reports filed with the SEC, are accurate and complete; and

 

·                   No employee should knowingly make (or cause or encourage any other person to make) any false or misleading statement in any of our reports filed with the SEC or knowingly omit (or cause or encourage any other person to omit) any information necessary to make the disclosure in any of our reports accurate in all material respects.

 

Any employee who becomes aware of any departure from these standards has a responsibility to report his or her knowledge promptly to a supervisor, Trovagene’s Corporate Compliance Officer or the Chair of the Audit Committee or by using one of the other compliance resources described in Section 26, “Compliance Standards and Procedures” , and/or in accordance with the provisions of Trovagene’s Whistleblower Policy for Accounting and Auditing Matters   Inaccurate, incomplete or untimely reporting can severely damage Trovagene or result in legal liability and will not be tolerated.  Trovagene employees should be on guard for, and promptly report, any possibility of inaccurate or incomplete financial reporting.  Particular attention should be paid to:

 

·                   Financial results that seem inconsistent with the performance of the underlying business;

 

·                   Transactions that do not seem to have an obvious business purpose; and

 

13



 

·                   Requests to circumvent ordinary review and approval procedures.

 

Trovagene’s executive officers have a special responsibility to ensure that all of our financial disclosures are full, fair, accurate timely and understandable.  Any practice or situation that might undermine this objective should be reported to supervisor, Trovagene’s Corporate Compliance Officer or the Chair of the Audit Committee or by using one of the other compliance resources described in Section 26, “Compliance Standards and Procedures”, and/or in accordance with the provisions of Trovagene’s Whistleblower Policy for Accounting and Auditing Matters.

 

Trovagene must retain certain types of documents and records for specific periods of time, because this is required under various laws and under Trovagene’s contracts with clients and others. These periods of time, and the types of documents and records covered, may vary.  Employees should not destroy or alter any document or record that may be the subject of any pending, threatened or likely claim, controversy or proceeding, whether investigative, administrative or judicial.  Employees are subject to any document retention policies of Trovagene then in effect.  Any questions concerning Trovagene’s document retention policies should be directed to the Corporate Compliance Officer.

 

21.        Competition and Fair Dealing

 

You should endeavor to deal fairly with customers, suppliers and competitors, and anyone else with whom you have contact in the course of performing your job.  Employees should not take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair-dealing practice.

 

21.1.                      Relationships with Customers

 

Our business success depends upon our ability to foster lasting customer relationships.  Trovagene is committed to dealing with customers fairly, honestly and with integrity.  Be aware that the Federal Trade Commission Act (the “FTCA”) provides that “unfair methods of competition in commerce, and unfair or deceptive acts or practices in commerce, are declared unlawful.”  It is a violation of the FTCA to engage in deceptive, unfair or unethical practices and to make misrepresentations in connection with sales activities.  Specifically, you should keep the following guidelines in mind when dealing with customers:

 

·                   Information we supply to customers should be accurate and complete to the best of our knowledge.  Employees should not deliberately misrepresent information to customers.

 

·                   Customer gifts and entertainment, when permitted, should not exceed reasonable and customary business practice.  Employees should not provide gifts or entertainment or other benefits to customers that could be viewed as an inducement to or a reward for, customer purchase decisions.  See Section 21.4, “Meals, Gifts and Entertainment” , for additional guidelines in this area.

 

21.2.                      Relationships with Suppliers

 

Trovagene deals fairly and honestly with its suppliers.  This means that our relationships with suppliers are based on price, quality, service and reputation, among other factors, and not on the receipt of special favors.  Employees dealing with suppliers should carefully guard their

 

14



 

objectivity.  Specifically, no employee should accept or solicit any personal benefit from a supplier or potential supplier that might compromise, or appear to compromise, their objective assessment of the supplier’s products and prices.  Employees can give or accept promotional items of nominal value or moderately scaled entertainment within the limits of responsible and customary business practice.  See Section 21.4, “Meals, Gifts and Entertainment”, for additional guidelines in this area.

 

21.3.                      Relationships with Competitors

 

We strive to outperform our competition fairly and honestly.  Advantages over our competitors are to be obtained through superior performance of our products and services, not through unethical or illegal business practices.  Acquiring proprietary information from others through improper means, possessing trade secret information that was improperly obtained, or inducing improper disclosure of confidential information from past or present employees of other companies is prohibited, even if motivated by an intention to advance our interests.  If information is obtained by mistake that may constitute a trade secret or other confidential information of another business, or if you have any questions about the legality of proposed information gathering, you must consult the Healthcare Compliance Officer or Corporate Compliance Officer.

 

Trovagene is committed to free and open competition in the marketplace. Employees should avoid actions that would be contrary to laws governing competitive practices in the marketplace, including federal and state antitrust laws.  Such actions include misappropriation and/or misuse of a competitor’s confidential information or making false statements about the competitor’s business and business practices.  For further discussion of appropriate and inappropriate business conduct with competitors, see Section 7, “Antitrust” .

 

21.4.                      Meals, Gifts and Entertainment

 

You shall not solicit or accept money, loans, credits, or prejudicial discounts, or accept gifts, entertainment, favors, or services from present or potential suppliers that might influence or appear to influence purchasing decisions.

 

You should make every effort to refuse or return a gift that is beyond Trovagene’s permissible guidelines.  If it would be inappropriate to refuse a gift or you are unable to return a gift, you should promptly report the gift to your supervisor.  Your supervisor will bring the gift to the attention of Trovagene’s Healthcare Compliance Officer or Corporate Compliance Officer, who may require you to donate the gift to an appropriate community organization.

 

These principles apply to the conduct of our business everywhere in the world, even where certain practices are widely considered a “way of doing business.”  If you conduct business in other countries, you must be particularly careful that gifts and entertainment are not construed as bribes, kickbacks or other improper payments.  For clarity, a “bribe” is anything of value given in an attempt to affect a person’s actions or decisions in order to obtain or retain business or to secure an unfair business advantage.  A “kickback” is the return of a sum already paid or due to be paid as a reward for awarding or fostering business.  See Section 6, “Anti-Corruption Laws”, for a more detailed discussion of our policies regarding giving or receiving gifts related to business transactions in other countries.  If you have any questions about whether it is permissible

 

15



 

to accept a gift or something else of value, contact your supervisor, Trovagene’s Healthcare Compliance Officer or Trovagene’s Corporate Compliance Officer for additional guidance.

 

21.5.                      Gifts, Meals and Entertainment Provided To or By Non-Customers

 

Trovagene recognizes that in some instances, gifts, meals and entertainment can provide an entirely appropriate means of furthering a business relationship.  Appropriate business gifts, meals and entertainment are welcome courtesies designed to build relationships and understanding among business partners.  Gifts, meals and entertainment, however, should not compromise, or appear to compromise, your ability to make objective and fair business decisions, and should not be (a) of excessive value, (b) in cash, (c) susceptible of being construed as a bribe or kickback, (d) made or received on a regular or frequent basis or (e) in violation of any laws.

 

It is your responsibility to use good judgment in this area.  As a general rule, you may give or receive gifts, meals or entertainment to or from suppliers, vendors and other non-customers only if the gift, meal or entertainment is consistent with customary business practices and would not be viewed as an inducement to or reward for any particular business decision.  All gifts, meals and entertainment expenses should be properly accounted for on expense reports.  The following specific examples may be helpful:

 

Meals and Entertainment.  You may occasionally accept or give meals, refreshments or other entertainment if:

 

·                   The items are of reasonable value;

 

·                   A primary purpose of the meeting or attendance at the event is business related; and

 

·                   The expenses would be paid by Trovagene as a reasonable business expense, if not paid for by another party.

 

Entertainment of reasonable value may include food and tickets for sporting and cultural events if they are generally offered to other suppliers or vendors.

 

·                   Advertising and Promotional Materials :  You may occasionally accept or give advertising or promotional materials of nominal value.  All advertising and promotional materials provided by Trovagene employees must be approved in advance by the Healthcare Compliance Officer.

 

·                   Personal Gifts :  You may accept or give personal gifts of reasonable value that are related to recognized special occasions such as a graduation, promotion, new job, wedding, birth of a child, retirement or a holiday.  A gift is also acceptable if it is based on a family or personal relationship and unrelated to the business involved between the individuals.

 

·                   Gifts Rewarding Service or Accomplishment :  You may accept a gift from a civic, charitable or religious organization specifically related to your service or accomplishment.

 

16



 

21.6.                      Gifts, Meals and Entertainment Provided To Customers

 

Trovagene does not provide any gifts or entertainment to health care professionals or other customers, including, without limitation, “reminder” gifts, such as branded mugs, pens, and notepads.  This prohibition applies irrespective of the cost of the item (there is no de minimis exception), and no company representative may use personal funds to provide anything of value to a health care professional that is otherwise prohibited.  Trovagene may provide occasional educational items to some health care professionals (except where state law further restricts or prohibits such gifts), but only if the value of the item (i) is less than $100, (ii) is used for physician or patient education, (iii) does not have independent value to a health care professional outside of his or her professional medical practice, and (iv) has been approved by the appropriate review process prior to use.  Examples of such items include: medical textbooks, subscriptions to scientific journals, copies of treatment guides, anatomical models, informational brochures, and patient starter kits.

 

Meals with health care professionals and other customers are generally prohibited, with the following exceptions:

 

·                   An occasional, modest meal may be provided in connection with an informational presentation, in an office or hospital setting or outside an office or hospital setting, when deemed appropriate, provided, (i) the place and manner are conducive to informational communication that provides scientific or educational value and (ii)  the location and cost comply with the restrictions set forth in Trovagene’s Travel and Entertainment Policy and Guidelines; and

 

·                   The meal is not in any way intended to influence or attempt to influence the purchase medical devices reimbursable by a federal or state reimbursement system.

 

A number of states have adopted more stringent requirements regarding the provision of gifts and meals to health care professionals and other customers, and Trovagene and its employees must also comply with these requirements.

 

The provision of entertainment or recreational items to health care professionals and other customers is strictly prohibited. A health care professional’s spouse or other guest(s) may not be invited to participate at an event where a meal is served, even if the health care professional offers to pay for the meal, unless the guest would independently qualify as a health care professional for whom the informational presentation would be appropriate.

 

21.7.                      Gifts, Meals and Entertainment Provided To Government Employees

 

Gifts, meals, and entertainment may not be offered or exchanged under any circumstances to or with any employees of the United States, state or local governments.  Under some statutes, such as the U.S. Foreign Corrupt Practices Act (further described under Section 6, “Anti-Corruption Laws” ), giving anything of value to a government official to obtain or retain business or favorable treatment is a criminal act subject to prosecution and conviction.  If you have any questions about this policy, contact your supervisor, Trovagene’s Healthcare Compliance Officer or Trovagene’s Corporate Compliance Officer for additional guidance.  For a more detailed discussion of special considerations applicable to dealing with the United States, state and local governments, see Section 18, “Interactions with the Government”.

 

17



 

22.        Protection and Proper Use of Trovagene Assets

 

All employees are expected to protect our assets and ensure their efficient use.  Theft, carelessness and waste have a direct impact on our profitability.  Our property, such as office supplies, computer equipment, buildings, reagents and products, are expected to be used only for legitimate business purposes, although incidental personal use may be permitted. You are also required to safeguard all electronic programs, data, communications and written materials from inadvertent access by others.  You may not, however, use our corporate name, any brand name or trademark owned or associated with Trovagene or any letterhead stationery for any personal purpose.

 

You may not, while acting on behalf of Trovagene or while using our computing or communications equipment or facilities, either:

 

·                   Access the internal computer system (also known as “hacking”) or other resource of another entity without express written authorization from the entity responsible for operating that resource; or

 

·                   Commit any unlawful or illegal act, including harassment, libel, fraud, sending of unsolicited bulk email (also known as “spam”) in violation of applicable law, trafficking in contraband of any kind, or espionage.

 

If you receive authorization to access another entity’s internal computer system or other resource, you must make a permanent record of that authorization so that it may be retrieved for future reference, and you may not exceed the scope of that authorization.

 

Unsolicited bulk email is regulated by law in a number of jurisdictions.  If you intend to send unsolicited bulk email to persons outside of Trovagene, either while acting on our behalf or using our computing or communications equipment or facilities, you should contact your supervisor or the Corporate Compliance Officer for approval.

 

All data and communications transmitted or received to or by, or contained in, Trovagene’s electronic or telephonic systems is the property of Trovagene.  Trovagene property also includes all written communications.  You have no expectation of privacy with respect to these communications and data.  To the extent permitted by law, Trovagene has the ability, and reserves the right, to monitor, retain and review, with or without an employee’s or third party’s knowledge, consent or approval, all electronic and telephonic communication in accordance with applicable law.  These communications may also be subject to disclosure to law enforcement or government officials.

 

You are also required to promptly report to your supervisor, Trovagene’s Corporate Compliance Officer or Healthcare Compliance Officer the actual or suspected theft, damage or misuse of Trovagene assets or property.

 

23.        Confidentiality

 

One of our most important assets is our confidential information.  As an employee of Trovagene, you may learn of information about Trovagene that is confidential and proprietary.  You also may learn of information before that information is released to the general public.  Employees who have received or have access to confidential information should take care to keep this information confidential.  Confidential information may include research, discovery and development activities, business, marketing

 

18



 

and service plans, financial information, product design, source codes, and manufacturing ideas, designs, databases, corporate partner or customer lists, buy-side or sell-side activity, pricing strategies, personnel data, personally identifiable information pertaining to our employees, customers, patients, partners or other individuals (including, for example, names, addresses, telephone numbers and social security numbers), and similar types of information provided to us by our customers, suppliers and partners.  This information may be protected by patent, trademark, copyright, privacy and trade secret laws.

 

In addition, because we interact with other companies and organizations, there may be times when you learn confidential information about other companies before that information has been made available to the public.  You must treat this information in the same manner as you are required to treat our confidential and proprietary information.  You must treat as confidential the fact that we have a current or potential interest in, or are involved with, another company.

 

You are expected to keep confidential and proprietary information confidential unless and until that information is released to the public through approved channels (usually through a press release, an SEC filing or a formal communication from a member of senior management, as further described in Section 24, “Corporate Communications Policy” ).  Every employee has a duty to refrain from disclosing to any person confidential or proprietary information about us or any other company learned in the course of employment here, until that information is disclosed to the public through approved channels.  This policy requires you to refrain from discussing confidential or proprietary information with outsiders and even with other Trovagene employees, unless those fellow employees have a legitimate need to know the information in order to perform their job duties.  Unauthorized use or distribution of this information could also be illegal and result in civil liability and/or criminal penalties.

 

You should also take care not to inadvertently disclose confidential information. Materials that contain confidential information, such as memos, notebooks, computer disks and laptop computers should be stored securely, both at the office and outside the office.  Unauthorized posting or discussion of any information concerning our business, information or prospects on the Internet is prohibited. You may not participate in or discuss our business, information or prospects in any social networking service (such as Facebook or Twitter), blog or chat room regardless of whether you use your own name or a pseudonym, or whether you access such locations from the office or outside the office.  Be cautious when discussing sensitive information in public places such as elevators, airports, restaurants and “quasi-public” areas within Trovagene, such as kitchens and restrooms.  All Trovagene emails, voicemails and other communications are presumed confidential and should not be forwarded or otherwise disseminated outside of Trovagene, except where required for legitimate business purposes.

 

You should also be aware that important federal and state laws govern the use and disclosure of confidential information about patients, including Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and Health Information Technology for Economic and Clinical Health Act (“HITECH”). HIPAA and HITECH impose strict limitations on the use and disclosure of protected health information (“PHI”) by “covered entities” and their “business associates.”  Although Trovagene itself—when engaging in functions such as clinical research and sales and marketing—is not subject to HIPAA and HITECH, Trovagene recognizes that many of the organizations with which it routinely interacts may be subject to these laws.  It is important to recognize the sensitive nature of patient information and maintain its confidentiality.

 

·                   Trovagene representatives should avoid situations in which the representative may be exposed to PHI without an individual’s consent. In the event a health care professional

 

19



 

(“HCP”) or other person exposes a representative to PHI, the representative should not document or reproduce the information in any media or form. The representative must strictly maintain the confidentiality of such information.

 

·                   Trovagene representatives should take reasonable steps to avoid inadvertently reviewing, seeing, hearing about, or otherwise learning about PHI when on-site at a covered entity and immediately return to the covered entity or destroy any paper or electronic copies of PHI that are inadvertently disclosed.

 

·                   Trovagene representatives should seek only de-identified data or non-patient identified prescriber data. Under limited and specific circumstances, and in consultation with Healthcare Compliance Officer, it may be appropriate for employees to receive certain “aggregated” or “de-identified” patient information from an HCP or other third party. “Aggregated” data is information about multiple individuals that is compiled and does not allow for the identification of any one individual. “De-identified” data is data that cannot be attributed to any specific individual or used to identify any individual and usually has been stripped of certain key identifiers which, either alone or in combination with other available information, could link the information with a specific individual or be used to identify a specific individual (including the individual’s name, many elements of the individual’s address, telephone number, and social security number, among others). HIPAA regulations include strict standards for what is “de-identified.” Accordingly, before assuming information is “de-identified,” consult the Healthcare Compliance Officer.

 

In addition to the above responsibilities, if you are handling information protected by any privacy policy published by us, such as our website privacy policy or that pertain to contractual agreements with partners or customers, then you must handle that information solely in accordance with the applicable policy.

 

24.        Corporate Communications Policy

 

Trovagene’s Corporate Communications Policy sets forth the guidelines that all Trovagene employees, consultants and representatives must follow in communicating information concerning Trovagene to the general public or to financial analysts, company stockholders, potential investors or media representatives. In general, communications with stockholders, investors, the media and market analysts are restricted to members of the executive management team and Investor Relations Department.   All inquiries from stockholders, potential investors, the media and market analysts must be directed to the Investor Relations Department for review and response by the appropriate representative.

 

25.        Waivers

 

Any waiver of this Code for executive officers (including, where required by applicable laws, our principal executive officer, principal financial officer, principal accounting officer or controller (or persons performing similar functions)) or directors may be authorized only by our Board of Directors or, to the extent permitted by the rules of NASDAQ, a committee of the Board, and will be disclosed to stockholders as required by applicable laws, rules and regulations (including, if required, the reasons for the waiver).  Waivers by any other employee may be authorized only by Trovagene’s Corporate Compliance Officer or Healthcare Compliance Officer.

 

20



 

26.        Compliance Standards and Procedures

 

26.1.                      Compliance Resources

 

To facilitate compliance with this Code, we have implemented a program of Code awareness, education and review.  We have established the positions of Corporate Compliance Officer and Healthcare Compliance Officer to oversee this program.  The Corporate Compliance Officer, Stephen Zaniboni, can be reached at (858) 967-8014, and the Healthcare Compliance Officer, Mark Erlander, can be reached at (858) 952-7641.  These Compliance Officers are individuals to whom you can address any questions or concerns.  In addition to fielding questions or concerns with respect to potential violations of this Code, the Compliance Officers are responsible for:

 

·                   Investigating possible violations of the Code;

 

·                   Educating new employees in Code policies;

 

·                   Conducting initial education sessions for newly hired employees to provide introductory education regarding the Code no later than the first full quarter following the employee’s date of hire;

 

·                   Conducting biennial education sessions to refresh employees’ familiarity with the Code;

 

·                   Distributing copies of the Code annually to each employee with a reminder that each employee is responsible for reading, understanding and complying with the Code;

 

·                   Updating the Code as needed and alerting employees to any updates, with appropriate approval of the Board of Directors, to reflect changes in the law, Trovagene’s operations and in recognized best practices, and to reflect Trovagene’s experience; and

 

·                   Otherwise promoting a corporate culture that promotes responsible and ethical conduct.

 

Your most immediate resource for any matter related to the Code is your supervisor.  He or she may have the information you need, or may be able to refer the question to another appropriate source.  There may, however, be times when you prefer not to go to your supervisor.  In these instances, you should feel free to discuss your concern with the Corporate Compliance Officer or Healthcare Compliance Officer.  If you are uncomfortable speaking with either of the Compliance Officers because he or she works in your department or is one of your supervisors, or for any other reason, you please contact the Chair of the Audit Committee of the Board of Directors via e-mail to ac@trovagene.com.  You may also report your concerns anonymously and without fear of reprisal by contacting the Company’s Hotline administered by Lighthouse Services, Inc., an independent third party, via the following methods:

 

(1)          Toll-Free Telephone:

 

·                   English speaking (USA and Canada): 844-280-0005

·                   Spanish speaking (USA and Canada): 800-216-1288

 

21



 

·                   Spanish speaking (Mexico): 01-800-681-5340

·                   French speaking (Canada): 855-725-0002

 

(2)          Website:  www.lighthouse-services.com/trovagene

 

(3)          E-mail:  reports@lighthouse-services.com (must include company name with report)

 

(4)          Fax:  215-689-3885 (must include company name with report)

 

Reports should be as detailed and complete as possible and include references to any supporting documentation in order to allow effective and efficient investigation.  Actions prohibited by this Code involving directors or executive officers must be reported directly to the Chair of the Audit Committee through the Company’s Helpline, the Trovagene Online Complaint Form or via e-mail, as described above.  Of course, if your concern involves potential misconduct by another person and relates to questionable accounting or auditing matters under Trovagene’s Whistleblower Policy for Accounting and Auditing Matters, you may report that violation as set forth in such policy.

 

26.2.                      Reporting Possible Violations; Anti-Retaliation Policy

 

Obligations to Make Reports and Procedures : If you encounter a situation or are considering a course of action and its appropriateness is unclear, discuss the matter promptly with your supervisor, the Corporate Compliance Officer, the Healthcare Compliance Officer or the Chair of the Audit Committee; even the appearance of impropriety can be very damaging and should be avoided.  If you are aware of a suspected or actual violation of Code standards by others, you have a responsibility to report it.  You are expected to promptly provide a compliance resource with a specific description of the violation that you believe has occurred, including any information you have about the persons involved and the time of the violation.

 

Supervisors must promptly report any complaints or observations of Code violations to the Corporate Compliance Officer, the Healthcare Compliance Officer or the Chair of the Audit Committee.  If you believe your supervisor has not taken appropriate action, you should contact the Corporate Compliance Officer or the Healthcare Compliance Officer.  The Corporate Compliance Officer or Healthcare Compliance Officer will investigate all reported possible Code violations promptly and with the highest degree of confidentiality that is possible under the specific circumstances.  Neither you nor your supervisor may conduct any preliminary investigation, unless authorized to do so by the Corporate Compliance Officer or Healthcare Compliance Officer.  Your cooperation in the investigation will be expected. As needed, the Corporate Compliance Officer or Healthcare Compliance Officer will consult with legal counsel, the Human Resources Department and/or the Board of Directors.  The Corporate Compliance Officer or Healthcare Compliance Officer the shall promptly inform the Audit Committee of any concerns and complaints regarding questionable accounting or auditing matters and shall promptly inform the Chair of the Audit Committee of all other reported material violations of the Code, including, without limitation, those involving officers.  We will strive to employ a fair process by which to determine violations of the Code.

 

Anti-Retaliation Policy :   Whether you choose to speak with your supervisor, Trovagene’s Corporate Compliance Officer, Trovagene’s Healthcare Compliance Officer or the Chair of the

 

22



 

Audit Committee, you should do so without fear of any form of retaliation.  If you report in good faith a suspected violation under the Code or raise issues or concerns regarding Trovagene’s business or operations, you may not be fired, demoted, reprimanded or otherwise harmed based solely on your reporting of the suspected violation, issues or concerns.  In addition, if you report in good faith a suspected violation under the Code which you reasonably believe constitutes a violation of a federal statute by Trovagene, or its agents acting on behalf of Trovagene, to a federal regulatory or law enforcement agency, you may not be reprimanded, discharged, demoted, suspended, threatened, harassed or in any manner discriminated against in the terms and conditions of your employment based solely on the reporting of the suspected violation, regardless of whether the suspected violation involves you, your supervisor or senior management.  We will take prompt disciplinary action against any employee who retaliates against you, up to and including termination of employment. This anti-retaliation policy is intended to protect you for your good faith reporting of the suspected or actual violation, but does not extend protection or provide a defense in the event of your own poor performance or violation or breach of the Code or the policies set forth in Trovagene’s Employee Handbook or employee agreements.

 

Procedures Upon Violation of the Code :  If the investigation indicates that a violation of the Code has probably occurred, we will take such action as we believe to be appropriate under the circumstances. If we determine that an employee is responsible for a Code violation, he or she will be subject to disciplinary action up to, and including, termination of employment and, in appropriate cases, civil action or referral for criminal prosecution.  Appropriate action may also be taken to deter any future Code violations.

 

27.        Acknowledgment Process

 

Trovagene requires each employee to sign an acknowledgment from time to time confirming that they have received the Code and understand that it represents a mandatory policy of Trovagene.  New employees are required to sign this acknowledgment as a condition of employment. Adherence to and support of the Code, as well as participation in related activities and training, are considered in decisions regarding hiring, promotion and compensation for all candidates and employees.  The form of acknowledgement is attached as Exhibit A to the Code.

 

23



 

Exhibit A

 

TROVAGENE, INC.

 

ACKNOWLEDGMENT OF RECEIPT AND REVIEW

 

To be signed and returned to the Corporate Compliance Officer.

 

I,                                              , acknowledge and confirm that I have received and read a copy of the Trovagene, Inc. Code of Business Conduct and Ethics.  I understand the contents of the Code and I agree to comply with the policies and procedures set out in the Code.  I understand that the Code represents a mandatory policy of Trovagene.

 

I understand that I should approach Trovagene’s Corporate Compliance Officer or the Healthcare Compliance Officer if I have any questions about the Code generally or any questions about reporting a suspected conflict of interest or other violation of the Code.

 

 

 

 

 

[SIGNATURE]

 

 

 

 

 

 

 

[PRINTED NAME]

 

 

 

 

 

 

 

[DATE]

 

24